U.S. Biotech Stock News

Wondering whether CRISPR Therapeutics at around US$46.24 is offering good value, or if the recent excitement is already priced in? This breakdown is designed to help you frame that question clearly. The stock is up 12.2% over the past year, even though it shows a 5.1% decline over 7 days, a 13.5% decline over 30 days, and a 14.0% decline year to date. Recent trading has therefore looked quite different to the longer term picture. Recent headlines around CRISPR Therapeutics have focused on...

Event context and recent share performance Merit Medical Systems (MMSI) shares have come under pressure recently, with the stock showing a 2.4% decline over the past day, 4.6% over the past week, and deeper pullbacks over the past month and past 3 months. See our latest analysis for Merit Medical Systems. The recent pullback, including a 30 day share price return of 18.9% decline and a year to date share price return of 22.8% decline, sits alongside a 1 year total shareholder return of 34.4%...

AptarGroup's Unidose Powder Nasal Spray System is being used in ENA Respiratory's Phase II trial for INNA-051. The trial targets prevention of symptomatic viral respiratory infections through a non-vaccine nasal approach. This use case highlights AptarGroup's role in advanced nasal drug delivery technologies within clinical pipelines. AptarGroup (NYSE:ATR) is widely known for drug delivery and consumer dispensing solutions, and this latest trial involvement puts its nasal systems in the...

MDU Resources Group (MDU) has drawn attention after recent trading, with the share price around $19.65 and mixed short term returns, including a 3.7% one day decline and 6.9% drop over the past week. See our latest analysis for MDU Resources Group. That recent 1-day share price return of negative 3.7% and 7-day return of negative 6.9% sit against a much stronger backdrop, with 1-year total shareholder return of 20.8% and 3-year total shareholder return of 93.6%. This suggests long term...

Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and upcoming Amtagvi melanoma regulatory decisions in the UK and Australia. See our latest analysis for Iovance Biotherapeutics. At a share price of $3.69, Iovance has given investors a 30 day share price return of 28.57% and a year to date share price return of 46.43%. However, the 5 year total...

Carvana stock moves after recent performance shift Carvana (CVNA) has drawn fresh attention after a recent pullback, with the share price down about 16% over the past month and roughly 35% over the past 3 months. See our latest analysis for Carvana. While the share price has given back ground recently, with a 1-day share price return decline of 4.39% and a 30-day share price return decline of 16.44%, the 1-year total shareholder return of 47.31% and very large 3-year total shareholder return...

Travere Therapeutics (TVTX) has drawn investor attention after recent trading left the shares with a loss of 32.1% year to date, despite a 30.7% total return over the past year. See our latest analysis for Travere Therapeutics. The current share price of US$26.84 sits well below its recent peak, with a 30 day share price return of an 8.4% decline and a year to date share price return of a 32.1% decline. At the same time, the 1 year total shareholder return is 30.7%, suggesting that earlier...

Hadrian and the U.S. Navy have agreed to work together to increase production of submarine parts. The partnership is aimed at supporting U.S. naval shipbuilding capacity and easing supply chain constraints. The move has potential implications for major submarine contractors, including General Dynamics (NYSE:GD). For investors watching General Dynamics at a current share price of $345.78, this new U.S. Navy and Hadrian partnership sits directly in the orbit of the company’s core submarine...

Apollo Global Management (APO) has been in focus after Apollo managed funds agreed to invest US$1.0 billion alongside Realty Income in a joint venture owning roughly 500 single-tenant, long-lease retail properties. See our latest analysis for Apollo Global Management. At a share price of US$112.0, Apollo’s recent 7 day share price return of 7.24% has come after a 90 day share price decline of 24.78%, while its 5 year total shareholder return of 166.66% points to strong longer term...

Alumis reported full-year 2025 results showing US$24.05 million in revenue and a net loss of US$243.33 million, while also filing a universal shelf registration and a US$300 million at-the-market follow-on equity offering alongside positive Phase 3 topline data for its TYK2 inhibitor envudeucitinib in plaque psoriasis. By pairing encouraging late-stage clinical data and plans for a 2026 New Drug Application with expanded financing flexibility, Alumis is signaling a push to advance...

Recent investor commentary has brought fresh attention to HEICO (HEI), after fund managers highlighted its volume growth compared with aerospace peers, continued margin expansion, and strong free cash flow, all tied to supply chain constraints and higher maintenance demand. See our latest analysis for HEICO. Despite HEICO's operational strengths gaining attention, the recent share price tells a different story, with a 1 month share price return of a 21.75% decline and a year to date share...

Sanmina (SANM) is drawing attention after recent share price moves, with the stock showing a 5.7% total return over the past year, along with multi-year gains and weaker performance in the past month. See our latest analysis for Sanmina. The recent 1 month share price decline of 17.0% and 1 day move of 5.7% lower sit in sharp contrast to a 1 year total shareholder return of 56.9%. This suggests longer term momentum while near term sentiment has cooled. If Sanmina's recent swing has you...

If you are wondering whether Intuitive Surgical at around US$477.97 is a bargain or already pricing in high expectations, you are not alone. The stock has returned 1.2% over the last 7 days, after a 5.2% decline over 30 days and a 14.9% decline year to date, while the 1 year return sits at a 2.9% decline and the 3 and 5 year returns are 86.4% and 96.2% respectively. Recent coverage has focused on how Intuitive Surgical fits into longer term themes in medical technology and how sentiment has...

PitchBook, a Morningstar subsidiary, was named one of G2's top-rated financial services software products for 2026, reflecting customer driven ratings. Morningstar (NasdaqGS:MORN) announced the winners of its UK Awards for Investing Excellence, recognising firms and funds for investment research and stewardship in the UK market. For you as an investor, these updates highlight different sides of Morningstar’s business, from software and data through PitchBook to research and ratings under...

Opera (NasdaqGS:OPRA) and Celo have agreed a restructured, multi year partnership that makes Opera a major network stakeholder in the Celo ecosystem. The deal centers on MiniPay and a planned push to drive global stablecoin usage across up to 50 million Opera users. The partnership includes a 160 million CELO allocation, expansion of MiniPay into new markets, and grassroots roadshows to support user adoption. Opera, trading at $14.36, now ties a bigger part of its fintech plans to the Celo...

The sharp recent move in Hims & Hers Health (HIMS) comes after Novo Nordisk agreed to resume selling its weight loss drugs on the platform, ending a public legal dispute and restoring their commercial relationship. See our latest analysis for Hims & Hers Health. The renewed Novo Nordisk agreement and the appointment of a new Chief Communications Officer come after a volatile stretch, with a 40.88% 1 month share price return followed by a 37.18% 3 month share price decline and a 36.63% 1 year...

Earlier this week, US President Donald Trump and Japanese Prime Minister Sanae Takaichi announced a joint US–Japan energy investment plan in which GE Vernova and Hitachi will develop BWRX-300 small modular nuclear reactors in Tennessee and Alabama, alongside Japanese-backed natural gas power projects in Pennsylvania and Texas. This government-supported partnership could reshape GE Vernova’s long-term project pipeline by tying its nuclear and gas technologies directly to rising electricity...

Farmers National Banc (FMNB) has recently drawn investor attention after a period in which the share price showed mixed short-term performance, including a loss of 7.4% over the past month. See our latest analysis for Farmers National Banc. The recent 7.4% 1 month share price return decline and 9.2% 3 month share price return decline contrast with a 2.0% 1 year total shareholder return. This suggests that momentum has cooled even as longer term holders remain modestly ahead. If this kind of...

Wondering if Hess Midstream at around US$39.59 is still offering value, or if most of the easy gains are already on the table. The stock has returned 1.5% over the last 7 days, 4.5% over the last 30 days, 14.3% year to date and 0.4% over the past year, with very large returns over the past 3 and 5 years of 85.1% and 173.4% respectively. Recent coverage has focused on Hess Midstream's role as a midstream infrastructure provider and how that positions the company within the broader energy...

Tidewater stock snapshot after recent moves Tidewater (TDW) has drawn investor attention after a recent pullback, with the share price down 2.4% on the day and 5.6% over the past week, despite strong 1 year and 3 year total returns. See our latest analysis for Tidewater. The recent 1 day and 7 day share price declines sit against a much stronger backdrop, with a 90 day share price return of 41.42% and a 1 year total shareholder return of 72.28%, suggesting momentum has cooled slightly after a...

Investors may be wondering whether Signet Jewelers, at around US$89 per share, still offers good value after a strong run, or if the current price already reflects most of the potential upside. The stock has returned 8.3% over the last 7 days, while the 30 day return is a 9.1% decline and the 1 year return is 55.8%. These moves may leave you questioning whether the recent swings signal opportunity or shifting risk. Recent coverage has focused on Signet Jewelers as a Specialty Retail name...

Event context and recent share performance monday.com (MNDY) has been drawing investor attention after a period of weak share performance, with the stock showing negative returns over the past month, past 3 months, year to date, and past year. Against that backdrop, investors are reassessing how the company’s US$1.23b in revenue and US$118.74m in net income align with its current market value of about US$3.75b and its recent value score of 2. See our latest analysis for monday.com. With the...

Wondering if Innospec, at around its recent US$65.89 close, is offering value or a value trap? This review breaks down what the current share price really reflects. The stock has recently seen a 4% decline over the past week, an 18.9% decline over the past month, and a 29.9% decline over the last year, which may signal that the market is reassessing both growth potential and risk. Recent coverage of Innospec has focused on its position within the chemicals sector and how investors are...

Wondering whether SentinelOne at around US$14.17 is starting to look like value or still carries a premium, especially after a weak year for the share price. The stock has slipped around 2.4% over the last week but is up about 9.3% over the last month, while the 1 year return sits at roughly 26.5% in the red and the year to date performance is around 3.2% lower. Recent coverage has focused on how investors are reassessing cybersecurity names in light of shifting risk sentiment and renewed...